Sponsor or institution
Clinical trials and research at Ting Therapeutics, INC.
As of November 12, 2026, Find a Trial lists 5 NIH-funded research projects at this institution, with $2.1 million in listed awards. Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5NIH research projects
NIH-funded research (5)
Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.
-
A drug to protect hearing during antibiotic treatment
A company-sponsored project is testing a drug to help prevent hearing loss in adults who must take aminoglycoside antibiotics.
-
Investigating a drug to prevent hearing loss caused by cancer treatment
This study is testing a new drug called TT002 to see if it can help prevent hearing loss caused by cisplatin, a chemotherapy drug that many cancer patients use, so that patients can keep their hearing while still getting the cancer treatment they need.
-
Using CDK2 inhibitors to prevent hearing loss caused by cancer treatment
This study is testing a new drug called TT001 to see if it can help prevent hearing loss in cancer patients who are receiving cisplatin chemotherapy, so they can keep their hearing while still getting the treatment they need.
-
Developing drugs to prevent hearing loss caused by certain antibiotics
This study is looking at a new medicine called TT003, made from a natural pepper, to see if it can help protect your hearing while you take certain antibiotics that can sometimes cause hearing loss, and if it works well, it could be a great option for people needing these antibiotics.
-
Protecting hearing from certain powerful antibiotics
A company is developing a medicine to protect adults from hearing loss caused by aminoglycoside antibiotics.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.